4//SEC Filing
Broadfin Healthcare Master Fund Ltd 4
Accession 0001103021-22-000047
CIK 0001103021other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:30 PM ET
Size
11.4 KB
Accession
0001103021-22-000047
Insider Transaction Report
Form 4
KOTLER KEVIN
Director
Transactions
- Conversion
Common Stock
2022-02-11$1.80/sh+2,422,222$4,360,000→ 7,588,395 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2022-02-11$10000.00/sh−436$4,360,000→ 0 total(indirect: See footnote)Exercise: $1.80From: 2022-02-11→ Common Stock (2,422,222 underlying)
Broadfin Capital, LLC
Director
Transactions
- Conversion
Common Stock
2022-02-11$1.80/sh+2,422,222$4,360,000→ 7,588,395 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2022-02-11$10000.00/sh−436$4,360,000→ 0 total(indirect: See footnote)Exercise: $1.80From: 2022-02-11→ Common Stock (2,422,222 underlying)
Transactions
- Conversion
Series B Convertible Preferred Stock
2022-02-11$10000.00/sh−436$4,360,000→ 0 total(indirect: See footnote)Exercise: $1.80From: 2022-02-11→ Common Stock (2,422,222 underlying) - Conversion
Common Stock
2022-02-11$1.80/sh+2,422,222$4,360,000→ 7,588,395 total(indirect: See footnote)
Footnotes (2)
- [F1]6,822,911 shares of Common Stock are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC, and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Broadfin Healthcare Master Fund, Ltd., Broadfin Capital, LLC, and Kevin Kotler affirmatively (i) disclaim beneficial ownership of the reportable securities, (ii) states that this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 ("Section 16") of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, except to the extent of their pecuniary interest therein, and (iii) disclaim being a "group" for purposes of Section 16.
- [F2]The securities may not be converted if, after such conversion, the Reporting Person would beneficially own, as determined in accordance with Section 13(d) of the Act, more than 9.98% of the Common Stock outstanding immediately after giving effect to such conversion. The securities do not have an expiration date, but the issuer may force conversion of the securities, subject to certain limitations.
Documents
Issuer
BIODELIVERY SCIENCES INTERNATIONAL INC
CIK 0001103021
Entity typeother
Related Parties
1- filerCIK 0001511900
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:30 PM ET
- Size
- 11.4 KB